Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest KemPharm Inc. Stories

2014-03-04 08:32:42

Composition of Matter Patents Issued in Multiple Countries for KemPharm's Lead Abuse-Deterrent Hydrocodone Prodrug CORALVILLE, Iowa, March 4, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that multiple global composition of matter patents have been issued for KP201 in Russia, Ukraine, Kazakhstan, Japan, Australia, New Zealand and South Africa....

2014-02-26 08:29:29

CORALVILLE, Iowa, Feb. 26, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that President and CEO, Travis Mickle, Ph.D., will present at the Cowen and Company 34(th) Annual Health Care Conference at the Boston Marriott Copley Place in Boston, MA. Among the topics to be discussed, Dr. Mickle will provide an overview of KemPharm's development pipeline,...

2014-02-05 08:29:57

CORALVILLE, Iowa, Feb. 5, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that president and CEO, Travis Mickle, Ph.D., will present at the 16(th) Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 16(th) Annual BIO CEO & Investor Conference will take place February 10-11 at the Waldorf Astoria in New...

2014-01-13 12:26:59

Richard Pascoe, CEO of Apricus Biosciences, and Joseph B. Saluri, Vice-President - General Counsel for Stine Seed Company, Added to KemPharm's Board CORALVILLE, Iowa, Jan. 13, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the appointment of Richard Pascoe, CEO of Apricus Biosciences, and Joseph B. Saluri, Vice-President - General Counsel, Stine Seed...

2014-01-09 12:26:30

CORALVILLE, Iowa, Jan. 9, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that president and CEO, Travis Mickle, Ph.D. will present at the Biotech Showcase(TM) 2014 Conference being held in San Francisco January 13-15, 2014. Among the topics to be discussed, Dr. Mickle will provide an overview of KemPharm's development pipeline, including KP201, the...

2013-12-04 16:25:35

NORTH LIBERTY, Iowa, Dec. 4, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that president and CEO, Travis Mickle, Ph.D. will present at the Oppenheimer 24(th) Annual Healthcare Conference being held in New York City December 10-11, 2013. Among the topics to be discussed, Dr. Mickle will provide an overview of KP201, the company's lead clinical candidate...

2013-11-01 08:27:09

Clinical, Non-Clinical and CMC Development Programs on Track for Third Quarter NDA Submission NORTH LIBERTY, Iowa, Nov. 1, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration (FDA) for its lead pain candidate, KP201 (benzhydrocodone hydrochloride and acetaminophen)....

2013-10-23 08:30:10

Pain Management Thought Leaders, Jeffrey A. Gudin, MD, and Srinivas Nalamachu, MD to Lead Council as Interest in Prodrug-Based Pain Therapeutics Builds NORTH LIBERTY, Iowa, Oct. 23, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has formed a Physician Advisory Council and named renowned pain specialists, Jeffrey A. Gudin, MD, and Srinivas Nalamachu,...

2013-09-25 08:30:22

Travis C. Mickle, Ph.D., President & CEO of KemPharm, to Present Results at The 7th Annual Pain Therapeutics Summit East NORTH LIBERTY, Iowa and BOSTON, Sept. 25, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, today announced results from a second pivotal clinical study of KP201 (benzhydrocodone hydrochloride and acetaminophen) in preparation for a New Drug Application...

2013-09-04 08:32:14

KP606 Introduced at PAINWeek 2013 NORTH LIBERTY, Iowa and LAS VEGAS, Sept. 4, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, today announced the advancement of a new pain therapy program, KP606, a first-in-class oral prodrug of oxycodone. KP606 adds to the Company's franchise of abuse-deterrent prodrugs, which includes KP201 (hydrocodone) and KP511 (hydromorphone)....